Related Experiment Videos
Preparation and characterization of a polyvalent human melanoma antigen vaccine
Abstract:
A polyvalent melanoma tumor antigen vaccine was prepared from antigens shed by a pool of human melanoma cells cultured in serum-free medium. The vaccine contained multiple melanoma associated antigens (MAAs) and was free of detectable fetal calf serum (FCS) proteins and Dr antigens. Three batches of vaccine prepared several months apart contained the same spectrum of tumor antigens. Thirteen patients with metastatic malignant melanomas were immunized intradermally with escalating doses of the vaccine in a Phase I study. There was no toxicity other than transient urticaria at the injection site. Humoral immunity, assayed by indirect immunoprecipitation, was augmented in five (38%) patients. Cellular immunity, assayed by delayed-type cutaneous hypersensitivity, was induced in four (31%) patients. Skin tests to a control vaccine prepared from pooled allogeneic lymphocytes were negative. Cutaneous metastases regressed completely in one patient who is now disease free after 2 years, and multiple cutaneous metastases have remained stable for 14 months in another patient. These results indicate that active immunization to a partially characterized polyvalent melanoma antigen vaccine is safe and can increase immunity to melanoma in some patients.
Insights
This study developed a safe, polyvalent melanoma antigen vaccine (MAAs) that boosted immune responses in patients with metastatic melanoma. Some patients experienced tumor regression, indicating potential for active immunization therapy.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Malignant melanoma is a significant health concern, necessitating novel therapeutic strategies.
- Development of effective melanoma vaccines requires identification and utilization of relevant tumor antigens.
- Previous vaccine formulations have faced challenges with antigen characterization and safety.
Purpose of the Study:
- To prepare and evaluate a polyvalent melanoma tumor antigen vaccine for safety and immunogenicity.
- To assess the clinical activity of the vaccine in patients with metastatic malignant melanoma.
Main Methods:
- A polyvalent melanoma vaccine was produced from shed antigens of human melanoma cells in serum-free culture.
- The vaccine's composition, including melanoma-associated antigens (MAAs), was analyzed.
- A Phase I clinical trial administered escalating doses intradermally to 13 metastatic melanoma patients.
Main Results:
- The vaccine was well-tolerated, with only transient urticaria observed.
- Humoral immunity was augmented in 38% of patients, and cellular immunity was induced in 31%.
- One patient achieved complete regression of cutaneous metastases and remains disease-free for 2 years; another had stable disease for 14 months.
Conclusions:
- Active immunization with this partially characterized polyvalent melanoma antigen vaccine is safe.
- The vaccine demonstrates the potential to enhance anti-melanoma immunity and induce clinical responses.
- Further investigation into this vaccine approach for melanoma treatment is warranted.